Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20292477 | 0.95 | TSPO (0.45) | LMNATP53ALOX15SMN1; SMN2TSPO | |
| SCHEMBL20292469 | 0.83 | MCL1 (0.41) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL725764 | 0.79 | MCL1 (0.49) | MCL1MAPK1SMN1; SMN2CA1CA2 | |
| SCHEMBL15015958 | 0.78 | CA12 (0.38) | MCL1MAPK1LMNATP53ALOX15 | |
| SCHEMBL480709 | 0.77 | TSPO (0.43) | LMNATP53ALOX15SMN1; SMN2TSPO | |
| SCHEMBL15016324 | 0.77 | CA12 (0.37) | MCL1MAPK1LMNATP53ALOX15 | |
| SCHEMBL416854 | 0.76 | TLR4 (0.55) | LMNATP53ALOX15SMN1; SMN2TSPO | |
| SCHEMBL20292355 | 0.76 | MCL1 (0.40) | MCL1MAPK1LMNAKMT2AALDH1A1 | |
| SCHEMBL535561 | 0.76 | MCL1 (0.49) | MCL1MAPK1SMN1; SMN2CA1CA2 | |
| SCHEMBL412877 | 0.75 | MAPK1 (0.43) | MCL1MAPK1LMNASMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995074-B2 | Amidine catalyst for curable compositions | SIKA TECHNOLOGY AG (CH) | 2021-05-04 | — | — | US | disclosed |
| EP-3558949-B1 | AMIDINE CATALYST FOR CURABLE COMPOSITIONS | SIKA TECH AG (CH) | 2020-09-30 | — | — | EP | disclosed |
| EP-3558949-A1 | AMIDINE CATALYST FOR CURABLE COMPOSITIONS | Sika Technology AG (CH) | 2019-10-30 | — | — | EP | disclosed |
| US-20190276412-A1 | AMIDINE CATALYST FOR CURABLE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2019-09-12 | — | — | US | disclosed |
| EP-2552891-B1 | TRICYCLIC INDOLE DERIVATIVES AS PBR LIGANDS | GE HEALTHCARE LTD (GB) | 2018-08-08 | — | — | EP | disclosed |
| WO-2018114476-A1 | AMIDINE CATALYST FOR CURABLE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2018-06-28 | — | — | WO | disclosed |
| EP-3339295-A1 | AMIDINE CATALYST FOR CURABLE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2018-06-27 | — | — | EP | disclosed |
| US-8501153-B2 | Active enantiomer | GE HEALTHCARE LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-8501153-B2 | Active enantiomer | GE HEALTHCARE LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| WO-2011117421-A1 | TRICYCLIC INDOLE DERIVATIVES AS PBR LIGANDS | GE HEALTHCARE LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
| US-20110070161-A1 | ACTIVE ENANTIOMER | GE HEALTHCARE LIMITED (GB) | 2011-03-24 | — | — | US | disclosed |
| US-20110070161-A1 | ACTIVE ENANTIOMER | GE HEALTHCARE LIMITED (GB) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070161-A1 | ACTIVE ENANTIOMER | GABRA5, GABRP, GABRA4 | MCL1 2933/4885MAPK1 4103/4885LMNA 3965/4885 |
| US-20190276412-A1 | AMIDINE CATALYST FOR CURABLE COMPOSITIONS | ARG1, ADM2, ARGLU1 | MCL1 928/4885MAPK1 892/4885LMNA 443/4885 |
| US-10995074-B2 | Amidine catalyst for curable compositions | ARG1, ADM2, ARGLU1 | MCL1 928/4885MAPK1 892/4885LMNA 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.